Xiaodong Yang

Pyxis Oncology is advancing a differentiated portfolio of potent biologics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies with the potential to help patients suffering from difficult-to-treat cancers.